Zalutumumab (proposed trade name HuMax-EGFr) is a fully human IgG1 monoclonal antibody (mAb) directed towards the epidermal growth factor receptor (EGFr). It is a product developed by Genmab in Utrecht, the Netherlands. Specifically, zalutumumab is designed for the treatment of squamous cell carcinoma of the head and neck, a type of cancer. The current treatment for SCCHN includes tyrosine kinase inhibitors and human monoclonal antibodies.
| Property | Value |
|---|---|
| dbpedia-owl:abstract |
|
| dbpedia-owl:atcPrefix |
|
| dbpedia-owl:casNumber |
|
| dbpprop:atcPrefix |
|
| dbpprop:c |
|
| dbpprop:casNumber |
|
| dbpprop:h |
|
| dbpprop:mabType |
|
| dbpprop:molecularWeight |
|
| dbpprop:n |
|
| dbpprop:o |
|
| dbpprop:s |
|
| dbpprop:source |
|
| dbpprop:target | |
| dbpprop:type |
|
| dbpprop:verifiedrevid |
|
| dbpprop:wikiPageUsesTemplate | |
| dcterms:subject | |
| rdf:type | |
| rdfs:comment |
|
| rdfs:label |
|
| owl:sameAs | |
| foaf:page | |
| is dbpedia-owl:wikiPageRedirects of | |
| is owl:sameAs of | |
| is foaf:primaryTopic of |



